AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 3/29/2019 |
| Start Date: | March 8, 2007 |
| End Date: | December 31, 2019 |
A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics
of a capsule of AZD6244 in patients with advanced solid malignancies.
of a capsule of AZD6244 in patients with advanced solid malignancies.
Inclusion Criteria:
- cancer which is refractory to standard therapies
- WHO performance status 0-2
- evidence of post-menopausal status or negative pregnancy test
Exclusion Criteria:
- Radiotherapy/chemotherapy within 21 days prior to entry
- brain metastases/spinal cord compression unless stable off steroids/anticonvulsants
- evidence of severe/uncontrolled systemic disease
- participated in an investigational drug study within 30 days
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials